摘要
Multi-session transarterial chemoembolization(TACE)is usually needed for the treatment of intermediate-stage hepatocellular carcinoma(HCC),but it may not always have a positive influence on prognosis due to high heterogeneity of HCC.To avoid ineffective repeated TACE,the concept of TACE failure/refractoriness has been proposed by several organizations and is being addressed using tyrosine kinase inhibitors.The concept of TACE failure/refractoriness is controversial due to ambiguous definitions and low evidence-based data.To date,only a few studies have examined the rationality concerning the definition of TACE failure/refractoriness,although the concept has been introduced and applied in many TACE-related clinical trials.This review focuses on some of the issues related to different versions of TACE failure/refractoriness,the rationality of related definitions,and the feasibility of continuing TACE after so-called failure/refractoriness based on published evidence.A suggestion to re-define TAEC failure/refractoriness is also put forward.
基金
Supported by the National Natural Science Foundation of China
No. 81901847
Natural Science Foundation of Jiangsu Province
No. BK20190177
the Suzhou Science and Technology Youth Plan
No. KJXW2018003
